Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects
- 2 March 2007
- journal article
- research article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 9 (1), 7-15
- https://doi.org/10.1007/s10198-006-0013-6
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Pneumococcal pneumonia in the UK—how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)Vaccine, 2005
- Cost-effectiveness studies of pneumococcal conjugate vaccinesExpert Review of Vaccines, 2004
- The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccineVaccine, 2003
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineNew England Journal of Medicine, 2003
- Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in GermanyPharmacoEconomics, 2003
- Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German childrenThe Pediatric Infectious Disease Journal, 2002
- The cost-effectiveness of routine childhood varicella vaccination in GermanyVaccine, 2002
- Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumoniaThe Pediatric Infectious Disease Journal, 2002
- Invasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine?Archives of Disease in Childhood, 2002
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000